Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

There's no doubt that Roche is playing catchup in the category, one of a lengthening list of pharma companies ... a once-daily formulation of its oral GLP-1 drug danuglipron as its preferred ...

Novo Nordisk gets CHMP backing for oral GLP-1 agonist Rybelsus in its marketing battle with Eli Lilly, plus positive opinions for Bayer’s diabetes drug Nubeqa, Emergent’s cholera vaccine, and more ...

A couple of months ago, healthcare equity research analyst Jared Holz from Mizuho spoke about Viking potentially being an ...

Ezekiel Emanuel and Dr. Ty Gluckman explore trends in patients stopping or restarting GLP-1 medications. This graph shows the time to discontinuation and reinitiation for patients with and without ...

Glucagon-like peptide 1 receptor agonist-based (GLP-1 RA) medications, including semaglutide and the dual GLP-1 RA/gastric inhibitory polypeptide (GIP) medication tirzepatide, have gained ...

That is perhaps why there has been so much buzz surrounding the class of drug known as a GLP-1 agonist.

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...